Article
Virology
Ting Shi, Linlin Huang, Zhengrong Chen, Jianmei Tian
Summary: This study investigated the characteristics of primary EBV infection and reactivation in children in Suzhou, China, finding that primary EBV infection was more common in children aged 36 to <72 months and often led to infectious mononucleosis. Reactivation of EBV mainly occurred in children aged 8 to <36 months and was identified as a risk factor for hemophagocytic lymphohistiocytosis (HLH). Among reactivated patients, HLH had a higher viral load compared to EBV infection and respiratory infection.
JOURNAL OF MEDICAL VIROLOGY
(2021)
Article
Pharmacology & Pharmacy
Hao Ji, Taihua Yang, Chunlai Li, Youwei Zhu, Zhigang Zheng, Jiaxu Zhang, Yuan Liu, Yijin Gao, Huimin Wu, Jinxing Jiang, Junekong Yong, Mengke Chen, Yuanjia Tang, Qiang Xia, Feng Xue
Summary: Post-transplant lymphoproliferative disorder (PTLD) is a serious complication after transplantation, with 80% of patients being positive for Epstein-Barr virus (EBV). However, monitoring EBV DNA load for preventing and diagnosing EBV-PTLD has limited accuracy. Therefore, there is an urgent need for new diagnostic molecular markers. This study discovered that BHRF1-1 and BART2-5p, elevated in EBV-PTLD patients, promote proliferation and suppress apoptosis. Mechanistically, they inhibit the tumor suppressor gene LZTS2 and activate the PI3K-AKT pathway. These findings suggest that BHRF1-1 and BART2-5p could serve as potential diagnostic markers and therapeutic targets for EBV-PTLD.
BIOCHEMICAL PHARMACOLOGY
(2023)
Article
Pharmacology & Pharmacy
Chloe Borde, Alexandre E. Escargueil, Vincent Marechal
Summary: Epstein-Barr virus (EBV) is a common herpesvirus that persists in most adults and is associated with malignancies. The virus transitions between latent and lytic phases, both contributing to tumor initiation. Recent studies have found that components of the NLRP3 inflammasome are involved in EBV reactivation. This study demonstrates that shikonin, apigenin, and OLT 1177, inhibitors of the NLRP3 inflammasome, effectively inhibit EBV reactivation.
ANTIVIRAL RESEARCH
(2023)
Article
Virology
Lingtong Huang, Xuan Zhang, Lisha Pang, Peng Sheng, Yanqiu Wang, Fan Yang, Huili Yu, Xiaohan Huang, Yue Zhu, Ning Zhang, Hongliu Cai, Lingling Tang, Xueling Fang
Summary: This study aimed to assess the landscape and clinical features of viral reactivation in the early onset of severe pneumonia in ICU patients. The most common reactivated viruses in the lower respiratory tract of patients with severe pneumonia were cytomegalovirus (CMV), herpes simplex virus-1 (HSV-1), and Epstein-Barr virus (EBV). Viral reactivation was associated with an increased risk of mortality.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Article
Clinical Neurology
Zhenye Li, Jianhua Li, Xiaosong Shan, Songbai Gui, Chuzhong Li, Yazhuo Zhang
Summary: The study found that low expression of p-Smad3 is correlated with the invasion of somatotropinomas. TGF-beta 1 and p-Smad3 scores were associated with invasion.
WORLD NEUROSURGERY
(2021)
Article
Immunology
Jing-Rui Zhou, Da-Yu Shi, Rong Wei, Yu Wang, Chen-Hua Yan, Xiao-Hui Zhang, Lan-Ping Xu, Kai-Yan Liu, Xiao-Jun Huang, Yu-Qian Sun
Summary: Reactivation of both cytomegalovirus and Epstein-Barr virus is common after hematopoietic stem cell transplantation and is associated with poor outcomes, including lower overall survival and leukemia-free survival rates. Co-reactivation of these viruses is also linked to prolonged viral duration and poor CD4+CD25+ T cell reconstitution post-transplantation.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Chung-Chun Wu, Ting-Ying Lee, Yu-Jhen Cheng, Der-Yang Cho, Jen-Yang Chen
Summary: Kaempferol efficiently inhibits the reactivation of EBV, making it a potential choice for anti-EBV therapy and cancer prevention.
Article
Infectious Diseases
Yun Xie, Song Cao, Hui Dong, Hui Lv, Xiaolei Teng, Jiaxiang Zhang, Tao Wang, Xiaoyan Zhang, Yun Qin, Yujing Chai, Luyu Yang, Jun Liu, Ruilan Wang
Summary: This retrospective single-center study found that COVID-19 patients with EBV reactivation had higher rates of tachypnoea, greater decreases in lymphocyte and albumin levels, higher levels of D-dimer and serum calcium, higher rates of CRP and occurrence of respiratory failure, ARDS, and hypoproteinaemia, as well as significantly higher 28-day and 14-day mortality rates compared to patients without EBV reactivation. These patients also received more immuno-supportive treatment.
BMC INFECTIOUS DISEASES
(2021)
Article
Oncology
Matthew A. Care, Sophie Stephenson, Roger Owen, Gina M. Doody, Reuben M. Tooze
Summary: Epstein-Barr virus (EBV) infects a high proportion of the human population and is maintained in an inactive latent state in memory B-cells. Reactivation of EBV can drive B-cell tumours. EBV mimics immune signals to activate B-cells and expand the virally infected population. Through single cell analysis, researchers identified recurrent cell states that EBV-associated B-cells adopt upon viral reactivation, providing a model for studying EBV-driven B-cell lymphoproliferation.
Article
Biochemistry & Molecular Biology
Praphatson Malat, Tipaya Ekalaksananan, Chukkris Heawchaiyaphum, Supawadee Suebsasana, Sittiruk Roytrakul, Yodying Yingchutrakul, Chamsai Pientong
Summary: Andrographolide inhibits the reactivation of Epstein-Barr virus in EBV-positive cancer cells by inhibiting EBV lytic genes, possibly through histone modifications.
Article
Virology
Keishanne Danielle E. Bernal, Christopher B. Whitehurst
Summary: COVID-19 patients have a higher frequency of EBV reactivation compared to COVID-19 negative patients, and COVID-19 positive patients exhibit higher levels of SARS-CoV-2 protein.
Article
Microbiology
Jeffrey E. Gold, Ramazan A. Okyay, Warren E. Licht, David J. Hurley
Summary: The study found a prevalence of 30.3% for long COVID symptoms among COVID-19 patients, with some initially asymptomatic patients developing long-term symptoms. Additionally, a significantly higher rate of EBV reactivation was observed in long COVID subjects compared to control subjects, suggesting a potential association between COVID-19 inflammation and EBV reactivation.
Article
Virology
Kena Lin, Zhiwen Zeng, Xueqi Li, Wenjie Chen, Dongfeng Lin, Shanghang Xie, Zhicong Wu, Mengmeng Li, Sumei Cao, Jinlin Du
Summary: This study investigated the association between hypertension and Epstein-Barr virus (EBV) reactivation. It found that hypertension increased the risk of EBV reactivation, while beta-blockers and angiotensin converting enzyme inhibitors (ACEIs) were associated with a reduced risk of EBV reactivation.
Article
Immunology
Yuhua Ru, Jinjin Zhu, Tiemei Song, Yiyang Ding, Ziling Zhu, Yi Fan, Yang Xu, Aining Sun, Huiying Qiu, Zhengming Jin, Xiaowen Tang, Yue Han, Chengcheng Fu, Suning Chen, Xiao Ma, Feng Chen, Jia Chen, Depei Wu
Summary: After haploindentical donor hematopoietic cell transplantation, the reactivation rates of EBV and CMV are higher and may have distinctive risk factors compared to HLA-matched HCT. Male recipients and acute graft-versus-host disease are independent risk factors for EBV and CMV reactivation. CMV reactivation is associated with worsened treatment-related mortality and progression-free survival, significantly impacting the survival of ALL patients. In the EBV+/CMV- subgroup, ALL patients have a lower relapse rate and better overall survival and progression-free survival compared to AML patients.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2022)
Article
Oncology
Janusz Klatka, Anna Szkatula-Lupina, Anna Hymos, Maria Klatka, Paulina Mertowska, Sebastian Mertowski, Ewelina Grywalska, Malgorzata Charytanowicz, Anna Blazewicz, Agata Poniewierska-Baran, Dominika Bebnowska, Paulina Niedzwiedzka-Rystwej
Summary: This study evaluated the level of PD-1 receptor in laryngeal cancer patients and healthy volunteers, and found that EBV infection may affect the PD-1/PD-L1 pathway and contribute to the development of laryngeal cancer. Additionally, the level of PD-1 on CD4+ T cells in lymph nodes was found to be a significant prognostic factor.
